TIDMORPH
Open Orphan PLC
09 April 2021
9 April 2021
Open Orphan plc
("Open Orphan" or the "Company")
Launch of Disease in Motion platform
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
pharmaceutical services clinical research organisation (CRO) and
world leader in vaccine and antiviral testing using human challenge
clinical trials , announces that hVIVO , a subsidiary of Open
Orphan, has officially launched its Disease in Motion(R) platform.
This unique data-focused platform includes clinical, immunological,
virological and digital (wearable) biomarkers. The Disease in
Motion platform has multiple infectious disease applications that
are applicable to a wide variety of end users including big tech,
wearables, pharma and biotech companies.
hVIVO has been at the forefront of running human challenge
studies for more than 20 years and has built up one of the most
comprehensive, multi-parametric bio and databanks ever created for
infectious diseases. This dataset from the Disease in Motion
platform is continuously gathered throughout the onset, progression
and resolution of an infection which is enabled by hVIVO's
challenge study model. The Company is committed to volunteer
patient data privacy and data is only collected from fully
consented volunteers in accordance with all relevant privacy
guidelines.
For more information on the platform, please visit
www.hvivo.com/DiseaseInMotion
Cathal Friel, Executive Chairman said: " The Disease in Motion
platform includes data from cutting edge wearables that are
applicable to a wide variety of end users including big tech,
wearables, pharma and biotech companies. As volunteers remain under
close observation prior to viral challenge, during disease
progression and until resolution, data is captured across the full
time-course of the infection, yielding possible insights into the
body's response to infection. The Disease in Motion platform
currently spans several conditions with plans to expand this going
forward.
As a recognised global leader in supporting the development of
therapeutics and vaccines, hVIVO and our team of virological,
clinical and regulatory experts are actively in discussion with
potential partners to help address the next set of challenges
facing humanity."
Interested in becoming a volunteer?
hVIVO recruits many of its volunteers for its challenge study
clinical trials through its dedicated volunteer recruitment
website, www.flucamp.com . By volunteering to take part in one of
our studies in a safe, controlled, clinical environment under
expertly supervised conditions you are playing your part to further
medical research and help increase the understanding of respiratory
illnesses.
Individuals interested in taking part in COVID-19 human
challenge study research can learn more at www.UKCovidChallenge.com
.
For further information please contact:
Open Orphan plc +353 (0) 1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser
and Joint Broker) +44 (0) 20 7614 5900
John Llewellyn-Lloyd / Benjamin Cryer
/ Dan Gee-Summons
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson/ Richard
Chambers
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780
Or openorphan@walbrookpr.com
Anna Dunphy / Paul McManus +44 (0)7876 741 001 / +44 (0)7980
541 893
Notes to Editors
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
pharmaceutical service/contract research company that is a world
leader in testing vaccines and antivirals using human challenge
clinical trials. The company provides services to Big Pharma,
biotech and government/public health organisations.
Open Orphan runs challenge studies in London from both its
19-bedroom Whitechapel quarantine clinic, opened in February 2021,
and its 24-bedroom QMB clinic which also has a highly specialised
virology and immunology laboratory on-site. Open Orphan has a
leading portfolio of eight human challenge study models for
conditions such as RSV, flu, asthma and COPD. In addition, Open
Orphan is also developing the world's first COVID-19 human
challenge study model as part of the Human Challenge Programme and
has signed a reservation contract with the UK Government for the
first three COVID-19 vaccine challenge studies.
Building upon its many years of challenge studies and virology
research, the Company is developing an in-depth database of
infectious disease progression data. Based on the Company's Disease
in Motion(R) platform, this unique dataset includes clinical,
immunological, virological and digital (wearable) biomarkers. The
Disease in Motion platform has many potential applications across a
wide variety of end users including big technology, wearables,
pharma and biotech companies. Following COVID-19 there is now a
renewed interest and investment in infectious diseases.
Open Orphan's Paris office has been providing biometry, data
management and statistics to its many European pharmaceutical
clients for over 20 years. For over 15 years, the Company's
Netherlands office has been providing drug development consultancy
and services, including CMC (chemistry, manufacturing and
controls), PK and medical writing, to a broad range of European
clients. Both offices are now also fully integrated with the London
office and working on challenge study contracts as well as
supporting third party trial contracts.
About Reach announcements
This is a Reach announcement. Reach is an investor communication
service aimed at assisting listed and unlisted (including AIM
quoted) companies to distribute non-regulatory news releases into
the public domain. Information required to be notified under the
AIM Rules for Companies, Market Abuse Regulation or other
regulation would be disseminated as an RNS regulatory announcement
and not on Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUWAKRAKUSRAR
(END) Dow Jones Newswires
April 09, 2021 02:00 ET (06:00 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jul 2023 to Jul 2024